John F Barrett

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi MRSA--what is it, and how do we deal with the problem?
    John F Barrett
    Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07065, USA
    Expert Opin Ther Targets 9:253-65. 2005
  2. ncbi Empirical antibacterial drug discovery--foundation in natural products
    Sheo B Singh
    Natural Products Chemistry, RY80Y 350, Merck Research Laboratories, P O 2000, Rahway, NJ 07065, USA
    Biochem Pharmacol 71:1006-15. 2006
  3. ncbi Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations
    Laura E Lawrence
    BMSPRI, Infectious Diseases, Department of Microbilogy, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 46:191-5. 2002
  4. ncbi American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USA
    John F Barrett
    Merck Research Laboratories, Rahway, NJ 07065-0900, USA
    IDrugs 6:639-42. 2003
  5. ncbi Antibacterial drug discovery & development summit
    John F Barrett
    Merck Research Laboratories, Rahway, NJ, USA
    Expert Opin Investig Drugs 13:715-21. 2004
  6. ncbi Recent developments in glycopeptide antibacterials
    John F Barrett
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Opin Investig Drugs 6:781-90. 2005
  7. ncbi MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance
    John F Barrett
    Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07650, USA
    Expert Opin Ther Targets 8:515-9. 2004
  8. ncbi Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa
    Chaowei Zhang
    Natural Products Chemistry, Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, New Jersey 07065, USA
    J Nat Prod 72:841-7. 2009
  9. ncbi Antibacterial evaluations of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa
    Sheo B Singh
    Merck Research Laboratories, Rahway, New Jersey, USA
    J Antibiot (Tokyo) 60:565-71. 2007
  10. ncbi Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa
    Chaowei Zhang
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Bioorg Med Chem 16:8818-23. 2008

Collaborators

  • Sheo B Singh
  • Hiranthi Jayasuriya
  • Oscar Salazar
  • Jun Wang
  • Lynn L Silver
  • Olga Genilloud
  • Liangsu Wang
  • Thomas J Dougherty
  • Emily Hickey
  • Kun Liu
  • Beth Junker
  • Laura E Lawrence
  • Lawrence B Snyder
  • Michael J Pucci
  • Peter Norman
  • Michael H Serrano Wu
  • D C Hooper
  • Chaowei Zhang
  • Claude A Quesnelle
  • Deborah L Zink
  • Prakash Masurekar
  • Katherine Young
  • Srinivas Kodali
  • Daniel B Davison
  • Charles E Mazzucco
  • Terry M Stickle
  • James Occi
  • Bruce Burgess
  • Misti Ushio
  • Russell Onishi
  • Kithsiri Herath
  • John G Ondeyka
  • Francisca Vicente
  • Sookhee Ha
  • Angela Basilio
  • Richard L Monaghan
  • Mengping Liu
  • Dennis Schmatz
  • Doris Cully
  • MaryBeth Frosco
  • Ronald Painter
  • Andrew Galgoci
  • Karen M Overbye
  • Alain Martel
  • Marco Dodier
  • Patrice Gill
  • Anne Marinier
  • Marta Perego
  • Christine T Barrett
  • Dolatrai M Vyas
  • Balu N Balasubramanian
  • Michael H Serrano-Wu
  • Jayashree Venugopal
  • Gwyneth Birdsall
  • Scott Smith
  • Charles Gill
  • Karen Dorso
  • Mary Motyl
  • Yingcong Zheng
  • Matthew D Healy
  • Phil Youngman
  • Robert E Bruccoleri
  • Robert Yamamoto
  • Kim M Esposito
  • Janet Sigmund
  • Brian A Dougherty
  • Vickie Brown-Driver
  • Trina C Maurice
  • Ying-Kai Wang
  • Judith I Ventura
  • Fernando Pelaez
  • John W Russell
  • Kithsiri B Herath
  • Stephan Roy
  • Kenneth S Santone
  • Joanne J Bronson
  • Jay O Knipe
  • Susan E Chaniewski
  • Junius Clarke
  • Hyekyung Yang
  • Ken L Denbleyker
  • Danielle Beaulieu
  • Cheryl A Ferraro
  • Glen A Warr
  • Dennis Taylor
  • Rebecca L Drain
  • Kathleen Mosure
  • Stanley V D'Andrea
  • James A Hoch
  • Michael Serrano-Wu

Detail Information

Publications31

  1. ncbi MRSA--what is it, and how do we deal with the problem?
    John F Barrett
    Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07065, USA
    Expert Opin Ther Targets 9:253-65. 2005
    ..Action must be taken to contain and eradicate MRSA through a combination of infection control, the development of novel anti-MRSA agents, development of vaccines and other non-traditional approaches of intervention...
  2. ncbi Empirical antibacterial drug discovery--foundation in natural products
    Sheo B Singh
    Natural Products Chemistry, RY80Y 350, Merck Research Laboratories, P O 2000, Rahway, NJ 07065, USA
    Biochem Pharmacol 71:1006-15. 2006
    ..This commentary provides an overview of current antibiotic leads and their mechanism of action, and highlights tools that can be applied to the discovery of new antibiotics...
  3. ncbi Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations
    Laura E Lawrence
    BMSPRI, Infectious Diseases, Department of Microbilogy, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 46:191-5. 2002
    ..7 and 61.6 mg/kg/day. BMS-284756 was more potent than levofloxacin and equipotent with moxifloxacin against ISP794 both in vitro and in vivo, while BMS-284756 was more potent than levofloxacin and moxifloxacin against 2C6(1)-1...
  4. ncbi American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USA
    John F Barrett
    Merck Research Laboratories, Rahway, NJ 07065-0900, USA
    IDrugs 6:639-42. 2003
  5. ncbi Antibacterial drug discovery & development summit
    John F Barrett
    Merck Research Laboratories, Rahway, NJ, USA
    Expert Opin Investig Drugs 13:715-21. 2004
    ..In addition, areas for basic research and development included metallo-beta-lactamases, ribosomal structural studies and phage-selected targets were described...
  6. ncbi Recent developments in glycopeptide antibacterials
    John F Barrett
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Opin Investig Drugs 6:781-90. 2005
    ..Among the leading development candidates are dalbavancin, oritavancin, telavancin and ramoplanin, each of which provides a unique microbiological and pharmacological profile to fill an important unmet medical need...
  7. ncbi MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance
    John F Barrett
    Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07650, USA
    Expert Opin Ther Targets 8:515-9. 2004
    ..Action must be taken to contain and eradicate MRSA through a combination of infection control and the development of novel anti-MRSA agents and vaccines...
  8. ncbi Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa
    Chaowei Zhang
    Natural Products Chemistry, Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, New Jersey 07065, USA
    J Nat Prod 72:841-7. 2009
    ..The isolation, structure elucidation, antibacterial activity, and proposed biogenesis of thiazomycins are herein described...
  9. ncbi Antibacterial evaluations of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa
    Sheo B Singh
    Merck Research Laboratories, Rahway, New Jersey, USA
    J Antibiot (Tokyo) 60:565-71. 2007
    ..Despite its positive attributes, emergence of an unacceptable frequency of resistance poses significant challenges for further development of thiazomycin and this class of molecules for therapeutic use...
  10. ncbi Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa
    Chaowei Zhang
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Bioorg Med Chem 16:8818-23. 2008
    ..7 microg/mL) and a potent Gram-positive antibacterial agent with minimum inhibitory concentration (MIC) ranging 0.002-0.25 microg/mL. The isolation and structure elucidation and biological activities of thiazomycin A are described...
  11. ncbi Discovery of FabH/FabF inhibitors from natural products
    Katherine Young
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Antimicrob Agents Chemother 50:519-26. 2006
    ..aureus. It exhibited a spectrum of antibacterial activity against clinically important pathogens including methicillin-resistant Staphylococcus aureus, Bacillus subtilis, and Haemophilus influenzae...
  12. ncbi Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347
    Chaowei Zhang
    Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Am Chem Soc 130:12102-10. 2008
    ..The design and execution of the bioassay, the isolation, structure, in vitro and in vivo antibacterial activity, and docking studies of philipimycin and its degradation product are described...
  13. ncbi Control and prevention of MRSA infections
    Liangsu Wang
    Infectious Disease Research, Merck and Co Inc, Rahway, NJ, USA
    Methods Mol Biol 391:209-25. 2007
    ..With the realization that MRSA is now a community problem, there are expanded efforts toward more direct intervention, such as the use of anti-MRSA antibacterials and vaccines, in an attempt to reduce the overall burden of MRSA...
  14. ncbi Isolation and structure elucidation of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa
    Hiranthi Jayasuriya
    Merck Research Laboratories, Rahway, New Jersey, USA
    J Antibiot (Tokyo) 60:554-64. 2007
    ..The isolation and structure elucidation of thiazomycin is herein described...
  15. ncbi Antibacterial drug discovery--then, now and the genomics future
    Richard L Monaghan
    Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07065, USA
    Biochem Pharmacol 71:901-9. 2006
    ..g., host metabolism differences), safety and the microbial genesis of chronic diseases (e.g., gastric ulceration)...
  16. ncbi Antibiotics: where did we go wrong?
    Karen M Overbye
    Antibacterial Discovery, Department of Infectious Diseases, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 08876, USA
    Drug Discov Today 10:45-52. 2005
    ..This decline in antibacterial drug discovery, coupled with increasing risk as a result of infections caused by drug-resistant bacterial pathogens, represents a clear public health threat...
  17. ncbi Can biotech deliver new antibiotics?
    John F Barrett
    Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Opin Microbiol 8:498-503. 2005
    ..So this leaves one with the question of 'can biotech deliver the new antibiotics?'...
  18. ncbi Pharmacoeconomics of treatment with the newer anti-Gram-positive agents
    Liangsu Wang
    Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA
    Expert Opin Pharmacother 7:885-97. 2006
    ..e., spectrum, activity, resistance emergence, efficacy, target, safety) provide a basis for an emerging pharmacoeconomic-based distinction between these newer anti-Gram-positive agents...
  19. ncbi Determination of selectivity and efficacy of fatty acid synthesis inhibitors
    Srinivas Kodali
    Department of Human and Animal Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Biol Chem 280:1669-77. 2005
    ..2 to 0.4 microg/ml. Furthermore, the effectiveness, selectivity, and the in vitro and in vivo correlations of BABX as well as other fatty acid inhibitors were elucidated, which will aid in future drug discovery...
  20. ncbi What are we looking for in new antibacterials and how do we design it?
    John F Barrett
    Expert Opin Investig Drugs 15:85-8. 2006
    ..To this end, the authors outline a few ideas regarding the changes in approach in order to accomplish these needs, including a fundamental change in the drug discovery process...
  21. ncbi Microbial genomics and novel antibiotic discovery: new technology to search for new drugs
    Thomas J Dougherty
    Department of Microbiology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Curr Pharm Des 8:1119-35. 2002
    ..Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program...
  22. ncbi Antibiotics and pharmacogenomics
    Daniel B Davison
    Bristol-Myers Squibb Pharmaceutical Research Institute, Lawrenceville, NJ 08534, USA. daniel.davison@ bms.com
    Pharmacogenomics 4:657-65. 2003
    ....
  23. ncbi Antibacterials: are the new entries enough to deal with the emerging resistance problems?
    Christine T Barrett
    Department of English, Princeton University, Princeton, NJ 08540, USA
    Curr Opin Biotechnol 14:621-6. 2003
    ..Although critical for certain resistance niche needs, these agents are unlikely to provide the solution to the requirement for a major novel scaffold class of antibacterials...
  24. ncbi Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials
    Lawrence B Snyder
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Bioorg Med Chem Lett 14:4735-9. 2004
    ..The synthesis and antibacterial activity of three such ring systems, the benzisoxazolinones, pyrroles, and isoxazolinones is described...
  25. ncbi Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics
    Michael J Pucci
    Achillion Pharmaceuticals, 300 George St, New Haven, CT 06511, USA
    Antimicrob Agents Chemother 48:3697-701. 2004
    ..These compounds demonstrated potential for further development as a new class of antibacterial agents with activity against key antibiotic-resistant gram-positive bacterial pathogens...
  26. ncbi Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery
    Mengping Liu
    Bristol-Myers Squibb Company Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Eukaryot Cell 5:638-49. 2006
    ..This work therefore demonstrates a streamlined process for proceeding from selection and validation of candidate antifungal targets to screening for specific inhibitors...
  27. ncbi Functional genomics of gram-positive microorganisms
    Marta Perego
    Division of Cellular Biology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Bacteriol 186:903-9. 2004
  28. ncbi Patent alert
    Peter Norman
    Noman Consulting, Burnham, Bucks, UK
    IDrugs 7:390-5. 2004
  29. ncbi Sordaricin antifungal agents
    Claude A Quesnelle
    Bristol Myers Squibb Pharmaceutical Research Institute, 100, boul de l Industrie, Candiac, Quebec, Canada J5R 1J1
    Bioorg Med Chem Lett 13:519-24. 2003
    ..The synthesis of homologated sordaricin as well as ether and ester derivatives is presented, and structural rearrangement products upon oxidation. These compounds were evaluated as agents to inhibit fungal growth...
  30. ncbi Oxime derivatives of sordaricin as potent antifungal agents
    Michael H Serrano-Wu
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Bioorg Med Chem Lett 12:943-6. 2002
    ..06 microg/mL. The antifungal activity was established to be exquisitely sensitive to the spatial orientation of the lipophilic side chains...
  31. ncbi Biaryl isoxazolinone antibacterial agents
    Claude A Quesnelle
    Bristol Myers Squibb Pharmaceutical Research Institute, Discovery Chemistry, Candiac, Quebec, Canada
    Bioorg Med Chem Lett 15:2728-33. 2005
    ..Extensive investigation of various substitutions on the phenyl ring was then undertaken. We report here, the synthesis and antibacterial activity of a series of biaryl isoxazolinone compounds...